ArticleDiabetologia2025
Autoimmune diseases and the risk and prognosis of latent autoimmune diabetes in adults.
Article in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- B Lymphocytes in Latent Autoimmune Diabetes in Adults: From Autoimmune Activation to Immunometabolic Heterogeneity and Precision Therapeutic Perspectives.Diabetes/metabolism research and reviews · 2026Review
- Integrative proteogenomic and observational analysis identifies potential biomarkers for latent autoimmune diabetes in adults.Cardiovascular diabetology · 2026Observational
- Latent autoimmune diabetes in Saudi adults aged 30-55 years old seen at a tertiary hospital in Riyadh, Saudi Arabia.Journal of family medicine and primary care · 2026Article
- Metabolic-epigenetic crosstalk in latent autoimmune diabetes in adults: potential roles of lactate-induced histone lactylation in immune regulation and pancreatic β-cell fate.Frontiers in endocrinology · 2026Review
- Risk of Hypoglycemia and Associated Factors Among In-Hospital Chinese Patients With Latent Autoimmune Diabetes in Adults (LADA): A Multicenter Retrospective Cohort Study.Journal of diabetes research · 2026Article
- Renal hypouricemia type 2 in a patient with latent autoimmune diabetes in adults: a case report and literature review.BMC nephrology · 2025Review
- Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2025Review
- Diabetes mellitus, metformin's target gene AMPK, and inflammatory bowel disease: A Mendelian randomization study.Medicine · 2025Article
- Clinical Characteristics and Related Risk Factors of Thyroid Dysfunction in LADA Patients: A Single-Center Cross-Sectional Study in Xuzhou, Jiangsu, China.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Against the Grain: Insulinoma-Associated Protein 2 Positive Latent Autoimmune Diabetes in Adults Defying Ethnic Prevalence Trends.AACE endocrinology and diabetesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aims/hypothesisThe aim of this study was to clarify the impact of autoimmune disease (AD) comorbidity on the risk and prognosis of latent autoimmune diabetes in adults (LADA).
methodsWe used data from a Swedish study comprising newly diagnosed cases of LADA (n=586, stratified into LADA
resultsIndividuals with ADs exhibit an increased susceptibility to LADA (OR 1.70; 95% CI 1.36, 2.13), particularly those with thyroid dysfunction (OR 1.88; 95% CI 1.38, 2.56), inflammatory bowel disease (OR 1.78; 95% CI 1.00, 3.16) or vitiligo (OR 3.91; 95% CI 1.93, 7.94), with stronger associations being observed for the LADA CONCLUSIONS/
interpretationWe confirm that several common ADs confer an excess risk of LADA, especially LADA with higher GADA levels, but having such a comorbidity does not appear to affect the risk of diabetic retinopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.